SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-222806"
 

Search: id:"swepub:oai:DiVA.org:uu-222806" > Diagnostic and prog...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • De Petris, LuigiKarolinska Institutet (author)

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • Elsevier BV,2011
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-222806
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-222806URI
  • https://doi.org/10.1016/j.ejca.2010.08.006DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:122079356URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE:Cytokeratin 18 (CK18) can be used as a serum biomarker for carcinoma cell death, whereas caspase-cleaved (ccCK18) fragments reflect tumour apoptosis. We explored the potential diagnostic and prognostic role of circulating CK18 and ccCK18 in patients with non-small-cell lung cancer (NSCLC) in comparison with Cyfra 21.1, a fragment of cytokeratin 19.METHODS:Subject cohorts consisted of 200 healthy blood donors (HBD), 113 patients with benign lung diseases (BLD) and 179 NSCLC cases. Plasma levels of ccCK18, total CK18 and Cyfra 21.1 were determined with ELISA assays.RESULTS:Plasma levels of ccCK18 and total CK18 were higher in the NSCLC group compared to the HBD and BLD cohorts (p<0.0001). Using a cut-off of 104 U/L for ccCK18 and 302 U/L for total CK18 (95% specificity in the HBD group) the diagnostic accuracy of both CK18 forms to distinguish between NSCLC and BLD cases was 56%, whereas it was 94% for Cyfra 21.1. Multivariate survival analysis showed that total CK18 was a stronger prognostic factor than both ccCK18 and Cyfra 21.1 (HR 0.64 for low versus high total CK18 levels, 95% confidence interval (CI) 0.50-0.82; p=0.0004) in the entire NSCLC cohort and in 78 patients with locally advanced or metastatic disease treated with chemoradiotherapy or first-line chemotherapy (HR 0.70 95% CI 0.52-0.94; p=0.018).CONCLUSIONS:Cyfra 21.1 is a useful diagnostic biomarker for NSCLC. Total CK18 shows a promising potential as prognostic marker in NSCLC patients, independently of the therapeutical intervention. In contrast, ccCK18 was not of prognostic value in NSCLC, suggesting that tumour necrosis is of particular importance in this disease.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Brandén, EvaUppsala universitet,Centrum för klinisk forskning, Gävleborg,Department of Respiratory Medicine, Gävle Hospital, Gävle, Sweden(Swepub:uu)evabr789 (author)
  • Herrmann, Richard (author)
  • Sanchez, Betzabe Chavez (author)
  • Koyi, HirshKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning, Gävleborg,Department of Respiratory Medicine, Gävle Hospital, Gävle, Sweden(Swepub:uu)hirko843 (author)
  • Linderholm, BarbroKarolinska Institutet (author)
  • Lewensohn, RolfKarolinska Institutet (author)
  • Linder, StigKarolinska Institutet (author)
  • Lehtiö, JanneKarolinska Institutet (author)
  • Karolinska InstitutetCentrum för klinisk forskning, Gävleborg (creator_code:org_t)

Related titles

  • In:European Journal of Cancer: Elsevier BV47:1, s. 131-1370959-80491879-0852

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view